Sunshine Bill Gains Momentum From PhRMA But Time May Be Running Short
Executive Summary
With an endorsement by the Pharmaceutical Research and Manufacturers America and three drug companies, momentum is building for Senate legislation to set up a federal reporting program for drug and device companies to disclose their gifts to physicians
You may also be interested in...
Revised Sunshine Act Pre-empts State Reporting Duplications, Not Differences
Senate Finance Committee Investigative Counsel Christopher Armstrong said the goal of pre-emption provisions in the latest version of the Physician Payment Sunshine Act is to create neither a floor nor ceiling for state reporting requirements, but merely to prevent duplicate reporting on state and federal levels
Revised Sunshine Act Pre-empts State Reporting Duplications, Not Differences
Senate Finance Committee Investigative Counsel Christopher Armstrong said the goal of pre-emption provisions in the latest version of the Physician Payment Sunshine Act is to create neither a floor nor ceiling for state reporting requirements, but merely to prevent duplicate reporting on state and federal levels
Some Clouds For PhRMA In Sunshine Act: Revised Bill Loosens Pre-emption
Sens. Herb Kohl, D-Wis., and Chuck Grassley, R-Iowa, have narrowed state pre-emption provisions in their latest Physician Payments Sunshine Act